Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
BioProcess Internation...BioProcess International US West
Not Confirmed
Not Confirmed
09-11 March, 2026
BioProcess Internation...BioProcess International
Not Confirmed
Not Confirmed
09-11 March, 2026
Not Confirmed
Not Confirmed
09-11 March, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BioProcess International US West
Not Confirmed
Contact SupplierBioProcess International US West
BioProcess Internation...BioProcess International US West
Industry Trade Show
Not Confirmed
09-11 March, 2026
BioProcess Internation...BioProcess International
Industry Trade Show
Not Confirmed
09-11 March, 2026
Industry Trade Show
Not Confirmed
09-11 March, 2026
Digital content
NEWS #PharmaBuzz
05 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/05/3250009/0/en/Altimmune-Announces-Fourth-Quarter-and-Full-year-2025-Financial-Results-and-Business-Updates.html
02 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/02/3247264/0/en/Altimmune-to-Participate-in-Upcoming-Investor-Conferences.html
29 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/29/3229184/0/en/Altimmune-Announces-Closing-of-75-Million-Registered-Direct-Offering-of-Common-Stock.html
05 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/05/3212638/0/en/Altimmune-Receives-FDA-Breakthrough-Therapy-Designation-for-Pemvidutide-in-MASH.html
19 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/19/3208385/0/en/Altimmune-Announces-that-Pemvidutide-Achieved-Key-Measures-of-Success-at-48-Weeks-in-IMPACT-Phase-2b-MASH-Trial.html
01 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/01/3196904/0/en/Altimmune-Announces-CEO-Transition-and-Succession-Plan.html
Drugs in Development
Details:
In the public offering, Pemvidutide, an unconjugated peptide targeting the GLP-1 receptor, aims to address metabolic dysfunction-associated steatohepatitis.
Lead Product(s): Pemvidutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Titan Partners
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 29, 2026
Lead Product(s) : Pemvidutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Titan Partners
Deal Size : $75.0 million
Deal Type : Public Offering
Altimmune Closes $75M Offering of Common Stock
Details : In the public offering, Pemvidutide, an unconjugated peptide targeting the GLP-1 receptor, aims to address metabolic dysfunction-associated steatohepatitis.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
January 29, 2026
Details:
Pemvidutide is a Peptide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Liver Diseases, Alcoholic.
Lead Product(s): Pemvidutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 08, 2025
Lead Product(s) : Pemvidutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pemvidutide Safety and Efficacy In Alcohol-Associated Liver Disease
Details : Pemvidutide is a Peptide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Liver Diseases, Alcoholic.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 08, 2025
Details:
Pemvidutide is a Peptide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Alcoholism.
Lead Product(s): Pemvidutide
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2025
Lead Product(s) : Pemvidutide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pemvidutide Safety and Efficacy In AUD Patients with Obesity/Overweight
Details : Pemvidutide is a Peptide drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Alcoholism.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 23, 2025
Details:
The Company’s lead program is ALT-801 (pemvidutide), a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD).
Lead Product(s): Pemvidutide
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 19, 2025
Lead Product(s) : Pemvidutide
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Altimmune Starts Phase 2 RECLAIM Trial of Pemvidutide in Alcohol Use Disorder
Details : The Company’s lead program is ALT-801 (pemvidutide), a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD).
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 19, 2025
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.
Lead Product(s): Pemvidutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 07, 2024
Lead Product(s) : Pemvidutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Altimmune Completes End-Of-Phase 2 Meeting with FDA for Pemvidutide
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
November 07, 2024
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.
Lead Product(s): Pemvidutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2024
Lead Product(s) : Pemvidutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide for MASH
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 30, 2024
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.
Lead Product(s): Pemvidutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2024
Lead Product(s) : Pemvidutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Altimmune Weight Loss Drug Shows Reduced Muscle Loss in Trials
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 28, 2024
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.
Lead Product(s): Pemvidutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 29, 2023
Lead Product(s) : Pemvidutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. It is being evaluated for the treatment of obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
November 29, 2023
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Lead Product(s): Pemvidutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2023
Lead Product(s) : Pemvidutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 26, 2023
Details:
ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Lead Product(s): Pemvidutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 12, 2023
Lead Product(s) : Pemvidutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALT-801 (pemvidutide) is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 12, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
Inspections and registrations
ABOUT THIS PAGE
Share 
